22 June 2017
May 2017 post
From April 29 to May 2 at the Palais des Congrès in Paris, the Heart Failure Association of the European Society of Cardiology held its annual meeting.
Within the program, I highlight a series of eleven 30-minutes hands-on tutorials on the use of the inodilator levosimendan in acute and advanced heart failure which were structured in several sessions touching the therapeutic needs and options, the comorbidities, the scientific evidence, the guidelines, and the clinical practice.
The take home message was that the inidilator levosimendan is a safe and valid therapeutic option for patients in advanced heart failure. Chairs and lecturers were from Austria (G.Pölzl, J.Altenberger), Italy (G.Malfatto), Hungary (Z.Papp), Finland (V.-P.Harjola, M.Kivikko), Sweden (K.Karason), Greece (J.Parissis), Denmark (F.Gustafsson), and Germany (D.Kindgen-Milles, C.Tschöpe).
The eleven lectures were collected on tape and can be now seen in YouTube format on a new dedicated educational channel (EPGonline Acute and Advanced Heart Failure)